Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| non-classical monocyte | 7 studies | 24% ± 7% | |
| neutrophil | 6 studies | 29% ± 9% | |
| classical monocyte | 6 studies | 25% ± 6% | |
| monocyte | 5 studies | 21% ± 3% | |
| alveolar macrophage | 3 studies | 24% ± 2% |
Insufficient scRNA-seq data for expression of FPR2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 99% | 900.69 | 574 / 578 | 59% | 2.43 | 683 / 1155 |
| spleen | 100% | 1601.63 | 240 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 82% | 9670.76 | 759 / 929 | 0% | 0 | 0 / 0 |
| stomach | 33% | 50.09 | 120 / 359 | 47% | 2.10 | 134 / 286 |
| intestine | 35% | 42.64 | 341 / 966 | 40% | 1.67 | 212 / 527 |
| adipose | 69% | 175.16 | 836 / 1204 | 0% | 0 | 0 / 0 |
| bladder | 33% | 50.43 | 7 / 21 | 34% | 1.35 | 169 / 504 |
| lymph node | 0% | 0 | 0 / 0 | 66% | 6.51 | 19 / 29 |
| adrenal gland | 60% | 55.15 | 155 / 258 | 4% | 0.12 | 9 / 230 |
| ovary | 47% | 50.34 | 84 / 180 | 13% | 0.26 | 55 / 430 |
| pancreas | 11% | 10.67 | 37 / 328 | 48% | 2.02 | 85 / 178 |
| kidney | 25% | 22.13 | 22 / 89 | 30% | 0.79 | 268 / 901 |
| esophagus | 22% | 23.92 | 313 / 1445 | 33% | 1.14 | 60 / 183 |
| breast | 39% | 37.97 | 181 / 459 | 10% | 0.25 | 113 / 1118 |
| liver | 44% | 46.94 | 99 / 226 | 5% | 0.08 | 19 / 406 |
| heart | 45% | 44.87 | 388 / 861 | 0% | 0 | 0 / 0 |
| uterus | 20% | 17.61 | 34 / 170 | 19% | 0.59 | 86 / 459 |
| blood vessel | 36% | 49.46 | 487 / 1335 | 0% | 0 | 0 / 0 |
| brain | 14% | 10.12 | 367 / 2642 | 21% | 0.90 | 150 / 705 |
| skin | 11% | 6.52 | 199 / 1809 | 23% | 0.56 | 109 / 472 |
| prostate | 25% | 24.06 | 61 / 245 | 3% | 0.05 | 15 / 502 |
| thymus | 20% | 15.42 | 131 / 653 | 7% | 0.17 | 40 / 605 |
| tonsil | 0% | 0 | 0 / 0 | 20% | 0.48 | 9 / 45 |
| muscle | 4% | 2.05 | 32 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0002768 | Biological process | immune response-regulating cell surface receptor signaling pathway |
| GO_0050766 | Biological process | positive regulation of phagocytosis |
| GO_0006954 | Biological process | inflammatory response |
| GO_0007200 | Biological process | phospholipase C-activating G protein-coupled receptor signaling pathway |
| GO_0019722 | Biological process | calcium-mediated signaling |
| GO_0050918 | Biological process | positive chemotaxis |
| GO_0090026 | Biological process | positive regulation of monocyte chemotaxis |
| GO_0006935 | Biological process | chemotaxis |
| GO_0007155 | Biological process | cell adhesion |
| GO_0045089 | Biological process | positive regulation of innate immune response |
| GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
| GO_0050728 | Biological process | negative regulation of inflammatory response |
| GO_0007204 | Biological process | positive regulation of cytosolic calcium ion concentration |
| GO_0007193 | Biological process | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway |
| GO_0042742 | Biological process | defense response to bacterium |
| GO_0032930 | Biological process | positive regulation of superoxide anion generation |
| GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
| GO_1904646 | Biological process | cellular response to amyloid-beta |
| GO_0007166 | Biological process | cell surface receptor signaling pathway |
| GO_0002430 | Biological process | complement receptor mediated signaling pathway |
| GO_0035579 | Cellular component | specific granule membrane |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0016020 | Cellular component | membrane |
| GO_0070821 | Cellular component | tertiary granule membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0101003 | Cellular component | ficolin-1-rich granule membrane |
| GO_0038023 | Molecular function | signaling receptor activity |
| GO_0004930 | Molecular function | G protein-coupled receptor activity |
| GO_0001540 | Molecular function | amyloid-beta binding |
| GO_0004982 | Molecular function | N-formyl peptide receptor activity |
| GO_0004875 | Molecular function | complement receptor activity |
| GO_0005124 | Molecular function | scavenger receptor binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | FPR2 |
| Protein name | N-formyl peptide receptor 2 (FMLP-related receptor I) (Formyl peptide receptor-like 1) N-formyl peptide receptor 2 (FMLP-related receptor I) (FMLP-R-I) (Formyl peptide receptor-like 1) (HM63) (Lipoxin A4 receptor) (LXA4 receptor) (RFP) |
| Synonyms | FPRH1 FPRL1 LXA4R |
| Description | FUNCTION: Low affinity receptor for N-formyl-methionyl peptides, which are powerful neutrophil chemotactic factors . Binding of FMLP to the receptor causes activation of neutrophils . This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system . The activation of LXA4R could result in an anti-inflammatory outcome counteracting the actions of pro-inflammatory signals such as LTB4 (leukotriene B4) . Receptor for the chemokine-like protein FAM19A5, mediating FAM19A5-stimulated macrophage chemotaxis and the inhibitory effect on TNFSF11/RANKL-induced osteoclast differentiation (By similarity). Acts as a receptor for humanin . . |
| Accessions | M0QXD3 M0R222 M0QZ89 ENST00000600258.1 ENST00000599326.1 ENST00000598953.1 ENST00000598776.1 ENST00000600722.1 ENST00000340023.7 P25090 |
